Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. trades under the ticker DECA following its business combination with Decathlon Acquisition Corp., a blank-check company that completed its initial public offering in 2021 targeting the healthcare and life sciences sector. Semnur is a clinical-stage pharmaceutical company focused on developing novel treatments for chronic pain, with its lead program addressing lumbar radiculopathy. The company filed a Form 10-Q with the Securities and Exchange Commission on August 12, 2022, providing a quarterly financial update as a newly public entity in the period following its de-SPAC transaction. Investors and analysts tracking Semnur's clinical pipeline and post-merger financials can sign up for full data, filing history, and deal analytics on SpacDesk.